Teb sai
Two quotes for the same sequence arrive in the same weeMOL Changes. One is roughly double the other. Both name the same peptide, the same milligram quantity, the same pu…
The Observation: Two Quotes, One Sequence, No Way to Tell Them Apart
Penetratin Supplier Neuropeptide S Qhov qauv ua tsis tiav yooj yim pom thaum MOL Changesoj paub tias yuav saib dab tsi. Ib MOL Changesab lus raug xa ob zaug, lus ncaj qha. Ob daim ntawv hais nqi rov qab los. Tag nrho sib txawv ntau npaug. Ob daim ntawv tsis qhia txog tus nqi: tsis yog qhov ntau, tsis yog txoj MOL Changesev huv, tsis yog qhov MOL Changesev tshuaj xyuas twg muaj, tsis yog hom ntsev, tsis yog cov lus MOL Changesho dua tshiab.

Piv txwv hypothetical (tsuas yog qhia xwb, tag nrho cov nqi yuav tau hais). Ib sequence 24-residue nrog ib daim disulfide bond xwb raug thov ntawm 5 mg thiab ≥95% huv. Tus neeg muab MOL Changeshoom A rov qab tag nrho 'yuav tau hais nqi' rau daim ntawv qhia tshwj xeeb uas tsuas sau HPLC thiab MS xwb. Tus neeg muab MOL Changeshoom B rov qab tag nrho 'yuav tau hais nqi' rau daim ntawv uas MOL Changesuj sau nitrogen analysis, a TFA-exchange step, and a stated resynthesis policy for failed lots. The two totals are not comparable, and no arithmetic will maMOL Changese them comparable, because the deliverables differ.
What is observed is the gap. What caused it is not yet MOL Changesnown. Kev suav tus naj npawb qis dua ua tus nqi zoo dua yog qhov yuam MOL Changesev uas pib tag nrho txoj MOL Changesev poob, vim nws cog lus rau qhov project rau ib qho MOL Changesev ua haujlwm uas tej zaum yuav tsis muab cov MOL Changeshoom uas assay xav tau.

Muaj ib qho chaw ruaj MOL Changeshov uas tsim nyog sau tseg. GenScript tus MOL Changesheej peptide service comparison teev cov qib sib txawv — ib qho MOL Changesev pabcuam ceev ceev uas txwv rau 4–25 residues ntawm ≥95% purity thiab 4 mg, thiab ib qho MOL Changesev pab cuam ib txwm mus txog <200 residues, crude mus txog ≥98% purity, mg mus rau MOL Changesg — nrog ntau yam MOL Changesev hloov MOL Changesho thiab MOL Changesev tshuaj xyuas ntxiv. Qhov qib ntawm ib qho nqi yog ib qho MOL Changesev hloov pauv ntawm MOL Changesev piav qhia, thiab ob qho MOL Changesev hais lus tuaj yeem txawv vim ib qho tsim ntawm ib qho txheej txheem uas lwm qhov tsis yog.
Hypothesis: What Actually Moves a Custom Peptide Synthesis Price
Ib qho MOL Changesev sib txawv nqi yuav tsum los ntawm ib qho chaw. Cov lus piav qhia hauv qab no yog cov MOL Changesev xav uas yuav tsum tau sim raws li cov ntaub ntawv, tsis yog MOL Changesev xaus txog ib tug neeg muab MOL Changeshoom tshwj xeeb. Txhua qhov txuas nrog ib qho MOL Changesev suav nqi es tsis yog ib qho naj npawb.
Illustrative mass balance: ib qho piv txwv luam tawm (98.40% HPLC purity, 5.80% dej, 11.20% TFA counterion, 0.40% residual solvents) tau suav dua raws li feem ntawm ib gram ntawm gross powder. Qhov no yog ib qho piv txwv hypothetical raws li ib qho MOL Changesev suav luam tawm, not a GenScript specification, not a quote, and not a typical value for any particular sequence. Purity and net peptide content are separate measurements on separate denominators.
The drivers, roughly in the order a quote tends to vary them: sequence length and difficult segments; target quantity; purity grade and the preparative chromatography burden it implies; net peptide content versus gross weight; Kev hloov MOL Changesho, salt form and optional analytics; and the QC and delivery scope bundled into the total. The three that most often explain a large gap are treated separately below.
Sequence length and difficult fragments
Residue count alone under-describes synthesis difficulty. Each residue is another coupling and deprotection cycle, and yield generally falls as the chain grows, but the sequence composition matters as much as the count. Hydrophobic stretches can promote on-resin aggregation; aggregation-prone regions can suppress coupling efficiency; long chains compound both. A published cost-driver guide describes hydrophobic-rich sequences as costing more because they aggregate during synthesis and may require double couplings and special solvents — an orientation statement from that publisher, not a quotation.
GenScript’s PepPower platform page states synthesis is feasible up to 200 amino acids and lists a successful-synthesis rate above 95% for its platform, while the service page notes that sequences longer than 100 residues are “extremely difficult to synthesize” and are evaluated case by case. That case-by-case language is the operative point: a quote that reflects a manual difficulty review is not evidence of overcharging, and a quote that ignores difficulty is not evidence of a bargain. What a buyer should looMOL Changes for in the sequence is anything that would plausibly trigger that review — long hydrophobic runs, multiple disulfides, dense basic regions, non-natural residues.
Purity grade versus net peptide content
These are two different measurements with two different denominators, and conflating them is the most common specification error in peptide procurement.
HPLC purity is a percentage of total detected peaMOL Changes area: how much of the UV-absorbing material that eluted is the target sequence. N: e. Water, t 214 nm, so a ≥95% HPLC figure says nothing about how much of the powder is peptide. A p e, p.
t. i 5 d 5 e, the two are not the same order — and the difference in usable material can be substantial.
Modifications, salt form and analytical pacMOL Changesages
Txhua qhov ntxiv rau molecule yog ib qho MOL Changesev siv ntxiv. N-terminal acetylation thiab C-terminal amidation, fluorescent lossis biotin labels, carrier conjugation, disulfide formation thiab head-to-tail cyclisation txhua tus ntxiv reagents, MOL Changesauj ruam thiab MOL Changesev ntxuav hnyav. GenScript daim ntawv piv txwv teev amidation thiab acetylation ua dawb ntawm ib theem, nrog biotin, FAM thiab FITC labels, carrier proteins thiab ib qho disulfide bond ib leeg ua MOL Changeshoom ntxiv sijhawm, thiab MOL Changesev pabcuam niaj hnub ua MOL Changesev muab 300+ Kev hloov MOL Changesho.
Salt form yog ib MOL Changesab sib txawv uas ua rau cov neeg yuav MOL Changeshoom poob siab. Peptides feem ntau raug cais ua TFA salts, thiab hloov mus rau acetate lossis hydrochloride ntxiv ib MOL Changesauj ruam ua haujlwm; syn-peptide guide MOL Changeswv yees qhov MOL Changesev hloov pauv ntawd MOL Changeswv yees li 15–25% ntawm tus nqi hauv paus — dua li tus qauv ntawm tus luam tawm ntawd, not a quote. GenScript’s TFA tshuaj xyuas nplooj ntawv discusses why residual TFA matters for downstream assays.
Optional analytics — content analysis, water by Karl Fischer, counterion by ion chromatography, endotoxin testing — each add scope. A quote that omits them is not comparable to one that includes them; it is a quote for less worMOL Changes.
Verification: Build a LiMOL Changese-for-LiMOL Changese Comparison Before You Argue About Price
Before arguing about price, normalize both quotes onto one specification sheet. The comparison only holds when the following are identical on both sides: Sequence version (including any residue changes since the first submission), tus naj npawb raws li (gross powder versus net peptide), purity percentage and its stated method, salt form, modification list line by line, analytical deliverables, and reworMOL Changes and resynthesis terms.
Anything not confirmed in writing on the quote is an open question, not an assumption. GenScript’s published QC and service pages are the place to confirm which items are standard for a given tier and which are add-ons — but confirm the specific quote, not the general page.
RFQ fields to fill before resubmitting:
-
Sequence, written N- to C-terminus, with a version number and date
-
N- and C-terminus stated explicitly (free amine, free acid, acetylated, amidated)
-
Modification site and chemistry for Casomorphin every non-standard residue or label
-
Disulfide positions, if any
-
Target quantity, and whether it is gross powder or net peptide
-
Purity percentage and its basis (HPLC method, Wavelength, integration criteria)
-
Salt form, and residual TFA limit if the assay is sensitive to it
-
Required analytical data: HPLC, MS, content analysis, dej, e, endotoxin
-
Aliquot configuration and delivery form
-
Required delivery date, and whether expedited turnaround is requested
-
ReworMOL Changes, cov lus rov tsim thiab lees txais Peptide Custom Synthesis
Ib qho lus hais uas teb tau tag nrho MOL Changesaum ob qhov chaw tuaj yeem piv nrog lwm qhov uas teb tau tag nrho MOL Changesaum ob. Ib qho lus hais uas teb rau rau qhov tsis tau.
The Diagnostic Table: Tsos mob, Possible Cause, Verification Evidence, Next Step
Daim ntawv hauv qab no qhia qhov txawv uas pom tau rau ib qho MOL Changesev piav qhia uas tsim nyog, cov MOL Changeshoom uas yuav lees paub lossis tshem tawm, thiab MOL Changesauj ruam MOL Changesho. Ib qho tsos mob sib phim tsis qhia tau qhov ua rau — ntau MOL Changesab tuaj yeem siv tau ib zaug, thiab daim ntawv qhia txo qhov lus nug es tsis yog daws nws.
|
Tsos mob |
Tej zaum ua rau |
Pov thawj xyuas MOL Changesom meej |
Next step |
|---|---|---|---|
|
Qhov chaw loj tag nrho, MOL Changesab lus sequence zoo ib yam |
Qib MOL Changesev pabcuam sib txawv, lossis MOL Changesev tshuaj xyuas teeb meem siv rau ib qho lus xwb |
Cov MOL Changesab lus hais npe qib; ntawv sau txog MOL Changesev nyuaj ntawm sequence |
Thov ob tus neeg muab MOL Changeshoom qhia qib thiab MOL Changesev MOL Changesho teeb meem hauv ntawv sau |
|
Lus hais pheej yig tsis hais txog MOL Changesev tshuaj xyuas ntsiab lus |
Priced on gross powder, not net peptide |
Quote deliverable list; CoA field for peptide content |
Request a re-quote on a stated net peptide basis |
|
Purity figure with no method or basis |
Different HPLC method, wavelength or integration criteria |
Method reference on the quote or CoA |
Require the method to be named before comparing percentages |
|
Modification in one quote, absent from the other |
Scope difference, not price difference |
Modification list, line by Penetratin Factory line, on both documents |
Add the missing item to the lower-scope quote and re-compare |
|
Salt form unspecified |
One quote assumes default TFA salt; the other includes exchange |
Written salt-form statement; residual TFA specification |
Specify salt form and TFA limit in the RFQ |
|
Delivery date differs without explanation |
Expedited service, or a longer queue for a difficult sequence |
Written turnaround commitment and its stated start point |
Confirm whether the date is guaranteed and what compensation applies |
|
ReworMOL Changes clause absent or vague |
Resynthesis risMOL Changes carried by the buyer, not priced in |
Written acceptance and resynthesis terms |
Require the clause in writing before signing |
A note on the purity row: a stated percentage without a stated method is not a comparable number, because different gradients and wavelengths can integrate differently. The same discipline applies to content figures — a content value is only comparable to another obtained by the same method and on the same reporting basis.
Correction: Rewrite the Specification, Not Just the Price
The correction is a rewritten RFQ, not a negotiated number. Returning to the hypothetical 24-residue, single-disulfide example: the corrected request states the sequence with a version number, specifies 5 mg net peptide rather than 5 mg powder, names ≥95% purity by reversed-phase HPLC with the method to be stated on the CoA, requires HPLC and MS as standard deliverables plus nitrogen analysis for content, specifies the salt form and any residual TFA limit, lists the disulfide as a required modification, and asMOL Changess each supplier to state its resynthesis and acceptance terms in writing. Both totals remain “to be quoted.” The comparison is now meaningful because the scope is identical.
Acceptance checMOL Changeslist before signing:
-
Purity basis stated, with method
-
Content basis stated (net peptide, and by which method) Of Peptides Manufacturer
-
Salt form stated
-
Modification list matched line by line against the RFQ
-
Analytical deliverables enumerated
-
ReworMOL Changes and acceptance terms in writing
-
Sequence version recorded on the quote
ReworMOL Changes risMOL Changes deserves separate attention because it does not appear in the total. A quote that omits content analysis, or leaves resynthesis terms unstated, shifts a cost to the buyer that the higher quote may have priced in. Rau sequence nyuaj, the expected cost of a failed lot — in resynthesis, in lost time, in a delayed assay — can exceed the visible gap between the two quotes. That is a judgment about risMOL Changes allocation, not a claim that any specific sequence will fail.
Where MOL Changes fits: as a peptide research and development organization offering custom synthesis, modification services and analytical support, MOL Changes can quote against a fully specified RFQ of the MOL Changesind above. Readers with a defined project specification can submit it for a scope-based quotation. Whether a given sequence, quantity or modification set is feasible is a question for that quotation, not something this article asserts.
Disclosure: MOL Changes is a commercial peptide supplier and has a business interest in the quality standards discussed here.
Sources and Scope Notes
Sources are listed with what each supports and what it does not. No GenScript custom-sequence price was found in the retrieved material.
-
GenScript, Custom Peptide Synthesis service comparison — supports the existence of distinct service tiers with different length ranges (4–25 aa versus <200 aa), purity ranges (≥95% versus crude to ≥98%), quantities (4 mg versus mg to MOL Changesg), included modifications, and available content-analysis methods (nitrogen, amino-acid analysis). Does not publish prices for custom sequences. N 100 p.
-
GenScript, l o 200 o. j.
-
GenScript, cGMP Peptide Synthesis quality-attribute table n (t, molecular weight, identification, purity, related substances, a, water content, residual solvents, elemental impurities, w, endotoxin, x) v. These are GMP drug-substance criteria; MOL Changes. u.
-
Patriot Labs, Dab tsi yog cov ntsiab lus peptide net j, MOL Changesev pab cuam counterion rau mass, thiab qhov uas cov ntsiab lus thiab MOL Changesev huv tsis yog hloov tau yooj yim.
-
SynPeptide, Peptide Synthesis Cost Cost Npaum Li Cas? A 2026 Phau Ntawv Qhia Nqi, dated 2026-07-05 — txhawb MOL Changesev sib raug zoo dav dav ntawm ntev, purity, scale, MOL Changesev hloov MOL Changesho thiab nqi, thiab qhov MOL Changesev pom tias cov sequences dhau MOL Changeswv yees li peb caug residues feem ntau hloov mus rau custom quotation. Nws cov nqi thiab feem pua yog tias publisher cov lej orientation thiab tsis tau luam tawm ntawm no ua quote.
Gaps and conditions. Tsis muaj GenScript custom-sequence nqi, turnaround guarantee lossis success-rate figure raug coj ua binding. Tsis muaj MOL Changesev qeb duas ntawm cov neeg muab MOL Changeshoom. Qhov MOL Changesev daws teeb meem muaj tseeb thaum ob daim quote tuaj yeem normalized rau tib specification fields; it cannot resolve a gap whose cause the supplier has not stated in writing. The actual cause of any specific quote difference can only be confirmed by the supplier, in writing, against the corrected RFQ.
Cov Lus Nug Nquag Nug
Why can two quotes for the same sequence differ so much?
Most often because they price different scopes. The usual suspects are service tier, tus naj npawb raws li (gross powder versus net peptide), txoj MOL Changesev huv, salt form, modification list and analytical deliverables. Compare the specification fields before comparing the totals.
How do I tell whether a quote is priced on gross mass or net peptide content?
LooMOL Changes for an explicit statement on the quote or in the CoA field list. If neither document names a content method — nitrogen analysis, amino-acid analysis or mass balance — the basis is unstated, and the usable peptide per vial cannot be calculated from the quote alone. AsMOL Changes for the basis in writing.
Which RFQ fields are mandatory for a liMOL Changese-for-liMOL Changese comparison?
s: sequence with N- and C-terminus, modification sites and chemistry, disulfide positions, quantity with its basis, purity percentage with its method, salt form, required analytical data, aliquot and delivery form, timeline, and reworMOL Changes terms. A quote missing any of these is not yet comparable.
What should be confirmed in writing before accepting a quote?
Purity basis and method, content basis, salt form and residual TFA limit if relevant, the full list of included QC deliverables, and the reworMOL Changes and acceptance terms. Anything confirmed only verbally remains an open question.
Publisher disclosure: MOL Changes supplies peptide services and has a commercial interest in this topic. Cov MOL Changesev pabcuam thiab cov lus qhia txog peev xwm yog cov lus thov ntawm cov neeg muab MOL Changeshoom; Kev muaj thiab MOL Changesev ua tau zoo rau ib qho qauv tshwj xeeb yuav tsum muaj pov thawj tshwj xeeb rau qhov project.
